Navigation Links
Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
Date:12/10/2008

k status and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE has been granted orphan-drug designation in the European Union and Australia.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainty whether the clinical trial results will allow the company to complete submission of a New Drug Application and if a New Drug Application submission is completed, uncertainty whether FDA will file or approve such application, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials or differences of opinion in interpreting the results of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's perio
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
2. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
3. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
4. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
5. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
6. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
7. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
8. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
9. Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... If you plan to attend the 27th annual ... will also want to sign up for the tour of Framingham State University's newest ... a walk through of the (8) chemistry teaching labs that are exclusively utilizing ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "DNA Sequencing - ... This report briefly reviews basics of ... their applications. Current large and small sequencers are ... applications of sequencing are described including those for ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... their offering. The markets for gene therapy ... approved gene therapy product and it is marketed in ... markets are estimated for the years 2014-2024. The estimates ...
(Date:9/2/2015)... Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., announced ... the multicenter Phase 2 clinical trial of NT-503 ... of recurrent subfoveal choroidal neovascularization secondary to age ... unique vascular endothelial growth factor (VEGF) receptor protein ... "This landmark proof-of-concept study will evaluate NT-503 ...
Breaking Biology Technology:Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4
... GLENWOOD, Ill., Aug. 29 Landauer, Inc. ... environmental radiation,monitoring, today announced the appointment of ... of Directors., Mr. Leatherman, currently an ... global contract negotiations, was,previously the Chief Financial ...
... Orexigen(R) Therapeutics,Inc. (Nasdaq: OREX ), a biopharmaceutical company ... obesity, today announced,that the Company will be presenting at ... the Biotech Industry Thursday, September 4, 2008, 10:00 ... UBS Global Life Sciences Conference Tuesday, September ...
... Barr Pharmaceuticals,Inc. (NYSE: BRL ) today ... approval from the U.S. Food & Drug Administration,(FDA) ... Ortho McNeil Janssen,s,Razadyne(R) (galantamine hydrobromide), 4 mg, 8 ... its generic Razadyne tablets product immediately., Barr ...
Cached Biology Technology:Landauer, Inc. Appoints Two New Members to Board of Directors 2Barr Receives Approval for Generic Version of Razadyne(R) Tablets 2Barr Receives Approval for Generic Version of Razadyne(R) Tablets 3Barr Receives Approval for Generic Version of Razadyne(R) Tablets 4Barr Receives Approval for Generic Version of Razadyne(R) Tablets 5
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/6/2015)... TELTOW, Germany , August 6, 2015 ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted ... this new solution, unprecedented quality and efficiency is brought ... context-sensitive displays. For the first time, professionals and researchers ...
(Date:8/5/2015)... , August 5, 2015 Transparency ... "Facial Recognition Market - Global Industry Analysis, Size, Share, ... market for facial recognition is forecast to reach US$ ... increased demand for surveillance systems by civil and government ... of crimes and terrorist activities across the globe that ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... discovery by scientists from the Mayo Clinic in Jacksonville, ... Disease that actually removes amyloid plaquesconsidered a hallmark of ... The FASEB Journal ( http://www.fasebj.org ), is ... immune cells (microglia) are activated by the interleukin-6 protein ...
... sequence was published in 2001, scientists have been working to figure ... a desert and finding a large book in a language you ... saying. "In the case of the human genome, the ... But we don,t yet understand its language," said Morgan Giddings, Ph.D., ...
... the Oct. 15 issue of the Journal of Clinical ... exercise program may benefit obese patients with mild to moderate ... condition. Results show improvement in typical OSA symptoms ... and mood after the completion of a 16-week diet and ...
Cached Biology News:Scientists remove amyloid plaques from brains of live animals with Alzheimer's disease 2UNC scientists win $1.6 million stimulus award to accelerate decoding of human genome 2Improved diet and exercise alone unlikely to cure obstructive sleep apnea in obese patients 2
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
Mouse monoclonal antibody raised against a partial recombinant NR4A2. NCBI Entrez Gene ID = NR4A2...
... power supply (Cat. No. Minis 300VS) is ... SDS-PAGE, and native PAGE applications. Furthermore, the ... pairs can be used simultaneously. The Minis ... have his/her own power supply in laboratories ...
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
Biology Products: